The first six months of 2014 proved to be the most active for US merger and acquisition (M&A) deals since the first half of 2007, according to The Mergermarket Group.
At US$694.6bn, US M&A deals were worth 98.3% more than H113 when they totaled US$350.2bn and increased by 30% from H213 (US$534.3bn), according to the ‘Mergermarket H1 2014 trend report’.
Among other key US findings from the report:
- Q214 was valued at US$405.2bn, an increase of 135.6% on Q213’s value of US$172bn and making Q214 the highest valued quarter since Q207.
- Compared to other world regions, the US experienced the largest increase in M&A from last year; its 44.2% share of the global market by deal value during H114 was up from 34.8% in H113.
- Private equity (PE) buyout value during H114, at US$80.1bn reached the second most active half year post-crisis, despite no mega-valued buyouts. H113 surpassed current levels only as a result of two mega-buyouts worth US$ 47.5bn.
Globally there were a total of US$1,571.2bn M&A deals over the first six months of 2014, a 56.3% increase over H113. The pharmaceutical, medical and biotech sector contributed US$258.6bn, a year-on-year (YoY) increase of 225.7%.
The H1 total for Europe was US$453.6bn and for Asia US$286.7bn, representing YoY increases of 35.5% and 56.8% respectively.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.